Related Experiment Videos
Induction of ovulation after gnRH antagonists
R Ron-El1, A Raziel, M Schachter
1IVF and Infertility Unit, Assaf Harofeh Medical Center, Zerifin, Israel. rronel@asaf.health.gov.il
Human Reproduction Update
|September 6, 2000
Summary
Gonadotrophin-releasing hormone (GnRH) antagonists suppress gonadotropin secretion, enabling controlled ovulation induction. They are crucial for preventing ovarian hyperstimulation syndrome (OHSS) and managing specific reproductive conditions.
Area of Science:
- Reproductive Endocrinology
- Pharmacology
Background:
- Gonadotrophin-releasing hormone (GnRH) antagonists competitively bind to pituitary receptors, inhibiting endogenous GnRH action.
- This blockade immediately suppresses gonadotropin secretion, offering a method for controlled ovarian stimulation.
Purpose of the Study:
- To explore the applications of GnRH antagonists in assisted reproductive technologies.
- To investigate the use of GnRH antagonists in preventing LH surge and managing OHSS risk.
Main Methods:
- Administration of GnRH antagonists (e.g., Cetrorelix) during the late follicular phase to delay the LH surge.
- Utilizing GnRH antagonists in various protocols for controlled ovarian stimulation and luteal phase support.
Main Results:
- Single administration of GnRH antagonist (3 or 5 mg Cetrorelix) effectively prevents the LH surge for 6-17 days.
- GnRH antagonists have four identified uses: ovulation triggering, OHSS risk reduction, luteal activity decrease, and LH/FSH ratio correction in PCOS.
Conclusions:
- GnRH antagonists are versatile tools in reproductive medicine, particularly for managing OHSS risk and optimizing controlled ovarian stimulation.
- Further research is needed to ascertain the impact of GnRH antagonist-induced LH surge delay on oocyte quality and maturation.